多西他赛联合表柔比星新辅助化疗治疗局部晚期乳腺癌疗效观察

Curative Effect Observation on Docetaxel Combined With Epirubicin Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Breast Cancer

目的研究多西他赛（DOC）联合表柔比星（EPI）新辅助化疗治疗局部晚期乳腺癌（LABC）的临床疗效。方法选择2010年2月~2014年8月我院84例LABC患者作为研究对象,根据化疗方案的不同分为两组,其中观察组48例行DOC联合EPI化疗,对照组36例行传统EPI＋5-氟尿嘧啶（5-FU）＋环磷酰胺（CTX）化疗方案,化疗结束后,随访观察1年,比较两组化疗效果及毒副作用。结果观察组总有效率和1年期生存率分别为92.75%和25.00%,高于对照组的77.78%和8.33%,差异有统计学意义（P〈0.05）。观察组骨髓抑制、胃肠道反应、静脉炎及脱发等毒副作用发生率低于对照组,差异有统计学意义（P〈0.05）。结论 DOC联合EPI新辅助化疗能改善局部晚期乳腺癌患者近期疗效,提高远期生存率,减少毒副作用的发生。

Objective To investigate the effect of docetaxel（DOC）combined with Epirubicin（EPI）neoadjuvant chemotherapy in treatment of locally advanced breast cancer（LABC）. Methods In our hospital,from February 2010 to August 2014,84 patients with LABC patients as the research object,according to different chemotherapy regimens for the two groups. The observation group,48 cases using DOC and EPI for combination chemotherapy and control group of 36 cases were treated by traditional EPI5- fluorouracil（5-FU）plus cyclophosphamide（CTX） chemotherapy. After chemotherapy,all patients were followed up for 1 year,compared two groups of chemotherapy effect and toxic and side effect. Results The total effective rate and 1 year survival rate of the observation group were 92.75% and 25.00%,respectively,significantly higher than that of the control group（77.78% and 8.33%）,the difference was statistically significant（P〈0.05）. In the observation group,the incidence of bone marrow suppression,gastrointestinal reaction,phlebitis and hair loss and other toxic side effects were significantly lower than that of the control group,the difference was statistically significant（P〈0.05）. Conclusion DOC combined with EPI neoadjuvant chemotherapy can significantly improve the short-term efficacy of locally advanced breast cancer patients,improve the long-term survival rate and reduce the toxic and side effects.